ExonHit Therapeutics informs shareholders about Highmark's intention to discontinue coverage of PathFinderTG

ExonHit Therapeutics (Paris:ALEHT) today informs its shareholders that it learned on June 16, 2010 from RedPath Integrated Pathology that Highmark (the Medicare reimbursement regional antenna for the states of Delaware, District of Columbia, Maryland, New Jersey and Pennsylvania) announced its intention to discontinue coverage of PathFinderTG® - Pancreatic cancer, contingent to a complementary assessment of the utility of the product.

Highmark's intention is preliminary and is based mainly upon data from 2006. RedPath has until July 9, 2010 to file a response to support coverage of its product. RedPath is currently putting together documentation that will contain the most recent medical data on the test and which will be supported by KOLs from the sector as well as peer reviewed scientific papers published a few months ago.

If the information filed by RedPath was considered satisfactory, Highmark would continue coverage. If Highmark considered, according to its criteria, that these elements were insufficient, coverage would be discontinued as of September 29, 2010.

ExonHit is currently evaluating the consequences that discontinuation of coverage could have on the acquisition in progress. The extraordinary shareholders' meeting scheduled on June 28, 2010 to decide on the acquisition project may be postponed.